Christoph Kausch
Managing Partner @ MTIP AG
Basel, Switzerland
Christoph Kausch is a Series A investor at MTIP AG in Basel focused on Health Care and Artificial Intelligence. Christoph Kausch has a sound knowledge in strategic management and bringing innovations to market. Before founding MTIP, he led the global strategy department of Syngenta for several years. Prior to this, he was Managing Director at Hafiba AG, a boutique investment company, where he still is a member of the board of directors. He started his careerat McKinsey & Company where he had specialized in private equity and life sciences. Christoph Kausch studied mechanical engineering at the TU Munich and at the Massachusetts Institute of Technology Management (MIT). He completed his PhD in innovation & technology management at the University of St. Gallen and at Harvard Business School.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Christoph Kausch invests in
Stages Christoph Kausch invests in
Countries Christoph Kausch invests in
Investment Focus
Industry
- Health Care 6 (67%)
- Artificial Intelligence 4 (44%)
- Medical Device 3 (33%)
- Medical 2 (22%)
- Software 2 (22%)
Stage
- Series A 4 (44%)
- Series C 2 (22%)
- Series B 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- United States 2 (22%)
- Spain 1 (11%)
- France 1 (11%)
- Israel 1 (11%)
- Sweden 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TrialBee
|
Trialbee is an independent software company dedicated to deliver solutions and services to the pharmaceutical industry. The company was founded in 2010 with the development of a method to increase speed and accuracy of patient recruitment to clinical trials. | Jan 07, 2026 | |
NitiNotes
|
Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair - both are needed to help obese patients reducing weight. | $9.3M / Series C / Dec 23, 2024 | |
Apricity
|
APRICITY is the world's first virtual fertility clinic. It aims at disrupting the fertility treatment experience and at improving chances for women and couples who have difficulties to conceive using data and Artificial Intelligence. The project is led by prominent entrepreneurs, medical practitioners, committed executives and data scientistswith a proven track record. | $16.9M / Series B / Sep 05, 2022 | |
LynxCare
|
LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $21.1M / Series A / Jun 21, 2022 | |
Intelligencia AI
|
Intelligencia is an enterprise SaaS company that applies Machine Learning to assess and mitigate the risk in clinical development strategy/design. | $12M / Series A / Aug 10, 2021 | |
Koa Health
|
Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions. The company's other products include Mindset, offered through providers as a way to facilitate privatechat-based mental health support.They create digital tools and resources for mental health that encompass prevention, prediction, and treatment. It offers a library of evidence-based activities for tackling stress, sleeping better, aiding relaxation and positive thinking, and boosting self-confidence. | $36.4M / Series A / Feb 09, 2021 | |
|
TrialBee
|
Trialbee is an independent software company dedicated to deliver solutions and services to the pharmaceutical industry. The company was founded in 2010 with the development of a method to increase speed and accuracy of patient recruitment to clinical trials. | $11.9M / Venture - Series Unknown / Apr 28, 2020 | |
|
NitiNotes
|
Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair - both are needed to help obese patients reducing weight. | $7.1M / Series A / Mar 16, 2020 | |
TytoCare
|
TytoCare is a mobile-health platform and device, allowing anyone to perform self physical examination and remote diagnosis.Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit andinclude a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use. TytoCare was founded by Dedi Gilad, Ofer Tzadik in 2012 with a vision to put health in the hands of the consumer. | $27.1M / Series C / Jan 29, 2018 |
Co-Investors
About MTIP AG
MTIP is a private equity investor specializing in the healthtech sector.
MTIP AG Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Christoph Kausch
Managing Partner
|
|||
Erich Platzer
Healthcare Partner & Member of the Board of Directors
|
|||
Felix Grisard
Chairman
|
|||
Hans Florian Zeilhofer
Board Member and Co-Founder
|
|||
Marco Gadola
Healthcare Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christoph Kausch invest in?
Christoph Kausch invests primarily in Health Care, Artificial Intelligence and Medical Device startups, most often at Series A and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christoph Kausch last invest?
The most recent investment recorded for Christoph Kausch closed in Jan 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
